Skip to main content
URGN logo

URGN · UroGen Pharma Ltd.

Track URGN — free
$29.79 -0.08 (-0.27%) At close · Nov 18
Market Cap
$1.46B
Shares
49.05M
Volume · Nov 18 1.14M Avg daily vol (3M) 1.09M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.79 Open$29.57 Day$28.15–30.17 52W close$17.00–50.29 Avg vol 30d1.4M Short int5.1M · 10.4% of shares · 5.1d Short vol66% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 1, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 10
Investor event
Fourth-Quarter Profitability Targeted After Third-Quarter Net Loss

UroGen Pharma Ltd. expects profitability and positive cash flow in the fourth quarter of this year despite a $1.5 million Q3 net loss and a $5 million PDUFA fee.

2 source passages
All right, so welcome to this next Fireside Chat with Eurogen Pharma. So we are right on the cost. If you looked, our net loss was $1.5 million in Q3, and with, one, the expected continued growth of this story, you know, as well as in Q3, we also had some one-time costs. For example, the $5 million PDUFA fee that we had for the 103 NDA filing, we expect to be profitable in the fourth quarter of this year. And importantly, we also expect to be cash flow positive in the fourth quarter of this year. Open the document at this passage
Nov 4
Earnings call
Revenue reaches $89 million; profitability expected in fourth quarter 2026

Urogen Pharma reported $89 million in revenue, expects profitability and positive cash flow in the fourth quarter of 2026, and received FDA acceptance of UGN 103 with a June 14, 2027 PDUFA goal date.

4 source passages
Thank you for standing by, and welcome to Urogen Pharma's third quarter, 2026 Earnings Conference Call. Total revenue was $89 million in the third quarter of 2026, compared with $27.5 million in the third quarter of 2025. Based on our current expectations, we anticipate achieving profitability and generating positive cash flow in the fourth quarter of 2026. Turning now to the pipeline, we achieved an important milestone with UGN 103, our next-generation investigational therapy for adults with recurrent low-grade intermediate-risk non-muscle-basic bladder cancer. Following our NDA submission in August, the FDA accepted the application for review in October and assigned a PDUFA goal date of June 14, 2027, representing another significant step toward potential approval. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly revenue reaches $89,001 thousand as net loss narrows

UroGen reported revenue of 89,001 thousand dollars for the quarter ended September 30, 2026, up from 27,482 thousand a year earlier. Its net loss narrowed to 1,462 thousand dollars from 33,347 thousand, and cash and marketable securities totaled $90.5 million as of September 30, 2026. The company believes it has sufficient cash to fund operations beyond one year.

Revenue $89M ▲ 223.9% Net loss $1.46M
Read from the first part of this long document
4 source passages
Revenue | 89,001 | 27,482 | 212,416 | 71,951 Net loss | (1,462) | (33,347) | (39,387) | (127,130) Cash and cash equivalents and marketable securities totaled $90.5 million as of September 30, 2026. the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Open the document at this passage
Nov 4
Current report 8-K
ZUSDURI revenue rises 35%; FDA accepts UGN-103 NDA

UroGen reported $68.0 million in third-quarter ZUSDURI revenue, up 35% from the second quarter of 2026, as the FDA accepted UGN-103's NDA for review with a June 14, 2027 PDUFA target date.

Financial results
2 source passages
ZUSDURI achieved net product revenue of $68.0 million in the third quarter of 2026, representing 35% growth over the second quarter of 2026. The FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$250.25M
Trailing 12 months
Net income (TTM)
−$65.75M
Trailing 12 months
Revenue growth YoY
+223.9%
Year over year
Operating margin
-12.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$108.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
+26.5%
Trailing year
Short interest
10.4%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. ZUSDURI revenue grew 35% sequentially as prescriber breadth and repeat utilization increased; total revenue rose to $89.0 million, and management expects fourth-quarter profitability and positive cash flow. JELMYTO revenue and guidance declined amid unfavorable adjustments and clinical-trial enrollment headwinds, while operating expenses are expected near the upper end of guidance and R&D, SG&A, and interest expense increased.

Bullish
  • + ZUSDURI generated $68.0 million in third-quarter 2026 revenue, representing 35% sequential growth.
  • + ZUSDURI adoption broadened and deepened, with 662 unique prescribers and 331 repeat prescribers.
  • + Total revenue increased to $89.0 million from $27.5 million in the prior-year quarter.
  • + The FDA accepted the UGN-103 NDA and assigned a PDUFA target action date of June 14, 2027.
  • + Management expects to achieve profitability and generate positive cash flow in the fourth quarter of 2026.
  • + A new patent is expected to provide coverage into July 2044 for ZUSDURI and, if approved, UGN-103.
Bearish
  • − JELMYTO third-quarter revenue declined to $21.0 million from $25.7 million in the prior-year quarter.
  • − Full-year JELMYTO revenue guidance was reduced to approximately $90 million from $97 million to $101 million.
  • − Full-year operating expenses are now expected near the upper end of the $260 million to $270 million range.
  • − Third-quarter R&D expenses increased to $26.0 million from $14.0 million in the prior-year quarter.
  • − Third-quarter SG&A expenses increased to $47.2 million from $37.6 million in the prior-year quarter.
  • − Long-term debt interest expense increased to $4.8 million from $3.4 million in the prior-year quarter.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −17%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 38%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −16%
trailing
6-month return +6%
trailing
YTD return +27%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $36 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +50 funds added
Insider flow Distributing
Net -$182.8K over 90 days · 100% sells
Short interest Falling
10.41% of shares out · ▼ -8.9% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
223 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Weak
Revenue growth −86%
Y/Y
Gross margin 8630%
expanding
Free cash flow $-162.7M
Balance sheet $14.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −51%
past year
ATR 7.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 4, 2026
Net product revenue for JELMYTO · full-year 2026 $90M
Operating expenses · full-year 2026 Maintained $260M – $270M
Aug 5, 2026 $260M – $270M changed to Nov 4, 2026 $260M – $270M
Non-cash share-based compensation expense · full-year 2026 Maintained $20M – $24M
May 6, 2026 $20M – $24M changed to Nov 4, 2026 $20M – $24M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Operating expense · full year 2026 $260M – $270M
Share-based compensation expense · full year 2026 $20M – $24M
Full year operating expense · full year $260M – $270M
Non-cash share-based compensation expense · full year $20M – $24M
Guided vs delivered · last 1 settled
Revenue full year 2021
guided $47M – $51M
$48.04M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
38% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $36 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +50 funds added
Insider flow Distributing
Net -$182.8K over 90 days · 100% sells
Short interest Falling
10.41% of shares out · ▼ -8.9% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
223 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17 Now $30 · 38% Range high $50
vs 200-day avg -6% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
activated sites of care 1,444 Q2 2026 —
repeat ZUSDURI prescribers 204 Q2 2026 —
repeat ZUSDURI prescribers as percent of total prescribers 45% Q2 2026 —
unique ZUSDURI prescribers 452 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
URGN
UroGen Pharma Ltd.
this stock
$1.46B +27.2% -86.2% — 10.4%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
223
% held
82.8%
Net QoQ
-1.8M sh
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
48
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
5.1d
Change
-499.4K sh
View
Short Volume
Short vol %
66%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
146.1K
Value
$5.3M
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
41.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$182.8K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$109.8M
Net income (FY)
$-153.5M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
20

UroGen Pharma Ltd. expects profitability and positive cash flow in the fourth quarter of this year despite a $1.5 million Q3 net loss and a $5 million PDUFA fee.

View
Proposed Sales
Value
$89.6K
Shares
2.2K
Filed
Oct 9, 2026
View
Exempt Offerings
Offering
$120.0M
Filed
Aug 14, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
UroGen’s Final Results from Olymp…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
URGN +14.1% -16.0% +5.9% -9.0% +27.2%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +18.0% -10.5% +9.4% -5.6% +20.1%
Key facts CIK 1668243 CUSIP M96088105 13F (30d) 229 filings 213 filers Visit website Investor relations